Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder

European Neuropsychopharmacology

Volumn 6, Issue 2, 1996, Pages 111-118

  Lopez Ibor Jr J J ^a   Saiz, J ^b   Cottraux, J ^c   Note, I ^d   Vinas R ^e   Bourgeois, M ^f   Hernandez M ^g   Gomez Perez J C ^h  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HÔPITAL NEUROLOGIQUE   (France)

^d HÔPITAL SAINTE MARGUERITE   (France)

^e Ctro Salud Mental (CSM) Fuencarral   (Spain)

^f Centre Carreire   (France)

^g Institute PET Dr Carreraas   (Spain)

^h Department of Clinical Research ^*  (Spain)

Author keywords

Clomipramine; Double blind; Fluoxetine; Obsessive compulsive disorder

Indexed keywords

CLOMIPRAMINE; FLUOXETINE;

ADULT; ANIMAL EXPERIMENT; ANOREXIA; ANXIETY; ARTICLE; ASTHENIA; CLINICAL TRIAL; COMPULSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OBSESSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; TREMOR; VERTIGO; XEROSTOMIA;

EID: 2542508830     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0924-977X(95)00071-V     Document Type: Article

References (42)

1. American Psychiatric Association (1987) The Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. revised. American Psychiatric Press, Washington, DC.
2. Asberg, M., Montgomery, S.A., Perris, C., Schalling, D. and Sedvall, G. (1978) A comprehensive psychopathological rating scale. Acta Psychiatr. Scand. 271, 5-9.
3. Chouinard, G., Goodman, W. and Greist, J.H. (1990) Results of a double blind serotonin uptake inhibitor sertraline in the treatment of obsessive compulsive disorder. Psychopharmacol. Bull. 26, 279-284.
4. The Clomipramine Collaborative Study Group (1991) Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry 48, 922-927.
5. Cottraux, J., Mollard, E., Bouvard, M., Marks, I., Sluys, M., Nury, A.M., Douge, R. and Ciadella, P. (1990) A controlled study of fluvoxamine and exposure in obsessive compulsive disorder. Int. Clin. Psychopharmacol. 5, 17-30.
6. Cottraux, J. (1993) Behavior therapy. In: Sartorius, N., Girolamo, G., Andrews, G., German, G.A. and Eisenberg, L. (eds.) Treatment of Mental Disorders: A Review of Effectiveness. American Psychiatric Press, Washington, DC.
7. Cottraux, J., Mollard, E., Bouvard, M. and Marks, I. (1993) Exposure therapy, fluvoxamine or combination treatment in obsessive-compulsive disorder: One-year followup. Psychiatry Res. 49, 63-75.
8. Covi, L., Lipman, R.S., McNair, D.M. and Czerlinsky, T. (1979) Symptomatic volunteers in multicentre drug trials. Prog. Neuro-Psychopharmacol. 3, 521-533.
9. De Veaugh Geiss, J., Landau, P. and Katz, R. (1989) Treatment of obsessive compulsive disorder with clomipramine. Psychiatr. Ann. 19, 97-101.
10. Flament, M.F., Rapoport, J.L., Berg, C.J., Scerry, W., Kilts, C., Mellstram, B. and Linnoila, M. (1985) Clomipramine treatment of childhood obsessive-compulsive disorder: A double blind controlled study. Arch. Gen. Psychiatry 42, 977-983,
11. Goodman, W.K., Price, L.H., Rasmussen, S.A., Delgado, P.L., Heninger, G.R. and Charney, D.S. (1989a) Efficacy of fluvoxamine in obsessive-compulsive disorder: A double blind comparison with placebo. Arch. Gen. Psychiatry 46, 36-44.
12. Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleishmann, R.L., Hill, C.L., Heninger, G.R. and Charney, D.S. (1989b) The Yale-Brown obsessive compulsive scale. I. Developement, use and reliability. Arch. Gen. Psychiatry 46, 36-44.
13. Goodman, W.K., Price, L.H., Delgado, P.L., Krystal, J.H., Nagy, L.M., Rasmussen, S.A., Heninger, G.R. and Charney, D.S. (1990) Specificity of serotonine reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine. Arch. Gen. Psychiatry 47, 577-585.
14. Hamilton, M. (1960) A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23, 56-62.
15. Heiligenstein, J.H., Tollefson, G.D. and Faries, D.E. (1993) A double-blind trial of fluoxetine 20 mg and placebo in out-patients with DSM-III-R major depression and melancholia. Int. Clin. Psychopharmacol. 8, 247-251.
16. Hewlett, W.A., Vinigradov, S. and Agras, W.S. (1990) Clonazepam treatment of obsessions and compulsions. J. Clin. Psychiatry 51, 158-161.
17. Jenike, M.A. and Rauch, S.L. (1994) Managing the patient with treatment-resistant obsessive-compulsive disorder: Current strategies. J. Clin. Psychiatry 55 (Suppl. 3), 11-17.
18. Karno, M., Golding, J., Sorenson, S. and Burnam, M.A. (1988) The epidemiology of obsessive compulsive disorder in five US communities. Arch. Gen. Psychiatry 49, 1094-1099.
19. Keijsers, G.P.J., Hoogduin, C.A.L. and Schaap, C.P.D.R. (1994) Predictors of treatment outcome in the behavioural treatment of obsessive-compulsive disorder. Br. J. Psychiatry 165, 781-786.
20. Lopez-Ibor, Jr. J.J. and Fernández-Cordoba, E. (1967) La monoclorimipramina en enfermos resistentes a otros tratamientos. Actas Luso-Españ. Neurol. Psiquiatría 26, 119-147.
21. López-Ibor, Jr. J.J. (1969) Intravenous perfusions of monochlorimipramine. Technique and results. In: Cerletti, A. and Bove, F.J. (Eds.), The Present Status of Psychotropic Drugs. Excerpta Medica, Amsterdam.
22. López-Ibor, Jr. J.J. (1988) What biological treatment teaches about the psychopathology of obsessive-compulsive disorders. Psychopharmacology 96, 24.
23. López-Ibor, Jr, J.J. (1990) Impulse control in obsessive-compulsive disorder; A biopsychopathological approach. Progr. Neuropsychopharmacol. Biol. Psychiatry 14, 709-718.
24. Marks, I.M. (1983) Are there anticompulsive or antiphobic drugs? Review of the evidence. Br. J. Psychiatry 143, 338-347.
25. Marks, I.M. (1987) Fears, Phobias and Rituals. Oxford University Press, Oxford.
26. Mavissakalian, M., Turner, S.M., Michelson, L. and Jacob, R. (1985) Tricyclic antidepressants in obsessive compulsive disorder. Antiobsessional or antidepressant agents? II. Am. J. Psychiatry 142, 301-306.
27. Mavissakalian, M., Jones, B., Olson, S. and Perel, J.M. (1990) Clomipramine in obsessive-compulsive disorder: Clinical response and plasma levels. J. Clin. Psychopharmacol. 10, 261-268.
28. McDougle, C.J., Goodman, W.K. and Leckman, J.F. (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch. Gen. Psychiatry (in press).
29. Montgomery, S.A. (1980) Clomipramine in obsessional neurosis: A placebo controlled trial. Pharm. Med. 1, 189-192.
30. Montgomery, S.A., McIntyre, A., Osterheider, M., Sarteschi, P., Zitterl, W., Zohar, J., Birkett, M. and Wood, A.J. (1993) A double blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur. Psychopharmacol. 3, 143-152.
31. Montgomery, S.A, and Åsberg, M. (1979) A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134, 382-389.
32. Murphy, D.L., Siever, L.J. and Insel, T.R. (1985) Therapeutic responses to tricyclic antidepressants and related drugs in non-affective disorder patient population. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 9, 3-13.
33. National Institute of Mental Health (1976) Clinical Global Impressions. In Guy, E. (Ed.), ECDEU Assessment for Psychopharmacology, revised edn. NIMH, Rockville, MD.
34. Perse, T.C., Greist, J.H., Jefferson, J.W., Rosenfeld, R. and Dar, R. (1987) Fluvoxamine treatment of obsessive compulsive disorder. Am. J. Psychiatry 144, 1543-1548.
35. Pigott, T.A., Pato, M.T., Bernstein, S.E., Grover, G.N., Hill, J.L., Tolliver, T.J. and Murphy, D.L. (1990) Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 47, 926-932.
36. Prasad, A. (1984) A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis. Pharmacopsychiatry 17, 61-62.
37. Rasmussen, S.A. and Eisen, J.L. (1990) Epidemiology of obsessive-compulsive disorder. J. Clin. Psychiatry 51 (Suppl.), 10-14.
38. Reimherr, F.W., Chouinard, G., Cohn, C.K., Cole, J.O., Itil, T.M., LaPierre, Y.D., Masco, H.L. and Mendels, J. (1990) Antidepressant efficacy of sertraline: A double-blind, placebo and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J. Clin. Psychiatry 51 (Suppl. B), 18-27.
39. Stoll, A.L., Tohen, M. and Baldessarini, R.J. (1992) Increasing frequency of the diagnosis of obsessive-compulsive disorder. Am. J. Psychiatry 149, 638-640.
40. Tollefson, G.D., Rampey, A.H., Potvin, J.H., Jenike, M.A., Rush, A.J., Dominguez, R.A., Koran, L.M., Shear, M.K., Goodman, W. and Genduso, L.A. (1994) A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry 51, 559-567.
41. Tollefson, G.D., Birkett, M., Koran, L. and Genduso, L. (1994b) Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. J. Clin. Psychiatry 55 (Suppl. 10), 69-76.
42. Yaryura-Tobias, J.A., Neziroglu, F. and Bergman, L. (1976) Clomipramine for obsessive neurosis: an organic approach. Curr. Ther. Res. 20, 541-547.